News

Public · Published

Shanghai RAAS Blood Products: YoY earnings fell, while sell-through improved and SR604 advanced to Phase III

Shanghai RAAS Blood Products reported third-quarter revenue and adjusted net profit that fell from a year earlier, though both reached 2026 highs and rose from the prior quarter. Sell-through and collections strengthened, SR604 advanced to Phase III, and a biologics facility acquisition was planned.

Published:

Updated:

What happened

Shanghai RAAS Blood Products reported third-quarter revenue and adjusted net profit that fell from a year earlier, though both reached 2026 highs and rose from the prior quarter. Sell-through and collections strengthened, SR604 advanced to Phase III, and a biologics facility acquisition was planned.

Confirmed

Global impact / market context

Lower yearly earnings show profit pressure, but quarter-on-quarter gains and better sell-through, which means products are selling through to customers, suggest demand and cash collection are improving. A Phase III trial, the final testing stage before approval, could add future revenue if successful.

Analyst inference

Investors are weighing weaker annual comparisons against recovering sales and cash collection. The planned biologics facility purchase would raise capital spending on manufacturing capacity, while SR604's late-stage trial adds regulatory and launch risk before any revenue arrives.

Analyst inference

What to watch

  1. Watch whether SR604 completes Phase III testing, the last stage before regulatory approval, and what results the trial produces. Confirmed
  2. Track the planned biologics facility acquisition, including its cost and funding, because buying manufacturing capacity affects capital spending and cash available. Proposed
  3. Monitor whether sell-through and collections keep improving, since stronger cash collection would support revenue quality and fund trial and facility costs. Analyst inference

Evidence

  • Original source link unavailable